Marpai Reports Second Quarter 2026 Financial Results

Marpai, Inc. (OTCQX: MRAI) reported Q2 2026 results for the three and six months ended June 30, 2026. Revenue fell to $8.6 million for six months ended June 30, 2026 from $10.1 million a year earlier. The company cited faster cost reductions improving gross margin, and amended debt maturities to 2028 and 2029. After quarter-end, it raised $12.1 million via a private placement.

Original reporting
Published Aug 13, 2026, 10:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 11:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Marpai Reports Second Quarter 2026 Financial Results — source image
Decision brief

The 30-second read

$MRAIBullishMed
01

Why it matters

The release combines operational metrics (cost of revenue down faster than revenue, improved gross margin) with capital structure actions (debt maturity extensions and a $12.1M private placement after quarter-end). This mix can reduce near-term solvency concerns while also raising questions about revenue stabilization and ongoing liquidity.

02

Market read

Traders get a fresh snapshot of turnaround progress (cost and gross margin improvement) alongside new financing and extended debt maturities, which can shift near-term risk perception.

03

What to watch

Unrestricted cash was $138k at June 30, so traders should focus on burn rate versus the timing/terms of the July 31 preferred financing and any future capital needs.

Relevance 7/10Novelty 6/10Timing: after-hours release of Q2 2026 results and post-quarter financing details

Background

Marpai is an OTCQX-listed healthcare technology and TPA/PBM services provider that is continuing a turnaround with customer pruning, cost-base adjustments, and AI-enabled process changes.

Company-level read

Ticker impact

$MRAIBullishMedium confidence
Context

Marpai reported Q2 2026 results showing lower operating costs, improved gross margin, and disclosed debt amendments plus a $12.1M preferred stock private placement.

Expected impact

Near-term bias modestly positive, with volatility likely around funding/cash burn and whether cost cuts translate into sustainable revenue stabilization.

Evidence & confidence

The article provides concrete cost and margin improvement drivers, and new capital structure details (debt maturity extensions and post-quarter $12.1M raise). However, revenue declined and unrestricted cash at June 30 was only $0.138M, limiting confidence in longer-term liquidity without further financing.

Market effects

Highlights cost-optimization and AI-driven efficiency efforts in TPA/PBM operators, but does not provide broader sector data.

No specific regional spillover beyond a Tampa-based issuer.

Limited global relevance; primarily company-specific turnaround and financing.

Counterpoint

Cost cuts and margin improvement may be temporary while customer pruning continues, so the stock could re-rate lower if revenue decline persists faster than expense reductions.

Key entities

  • Marpai, Inc.

    OTCQX-listed healthcare technology, TPA, and PBM services provider reporting Q2 2026 results, debt amendments, and a post-quarter preferred stock private placement.

  • Series A Preferred Stock (private placement)

    July 31, 2026 private placement generating $12.1M gross proceeds to support operations and strategic priorities.

  • Senior secured convertible debentures

    Amended in May 2026 to extend maturity to April 15, 2028 and revise amortization.

  • AXA notes

    Amended in July 2026 to extend maturity to 2029 and revise amortization and repayment schedules.

Related articles

$MRAIMedAI 8/10

Marpai Announces $12 Million Private Placement led by Mitchell Companies

Marpai, Inc. (OTCQX: MRAI) said it completed securities purchase agreements for a $12 million private placement of newly designated convertible preferred stock led by Mitchell Companies. The deal sold 12,100 shares at $1,000 each with a $1.00 initial conversion price. Preferred holders receive an 8% dividend in common shares and convert on a liquidity event or qualified public offering.

$NVDAMed

Copper Heads for Longest Weekly Losing Streak in Two Years

Copper prices fell 3.6% to $12,763/ton, heading for the longest weekly losing streak in two years. Nvidia (NVDA) reported $115.8B in Q3 revenue, beating estimates by $6.7B. Analysts cite AI selloff and dollar strength as factors. Copper is down 14% from its September record. Aluminum also declined, touching a near-year low.

$FCXMed

Freeport-McMoRan Stocks Fall 7.09% as Erste Downgrade Meets Slumping Gold

Freeport-McMoRan (FCX) shares fell 7.09% to $51.38 after Erste Group downgraded it to Hold, citing expected declines in copper and gold volumes and valuation concerns. The drop follows a 11% decline in a week. December gold futures also fell to $3,767.60 per ounce, impacting Freeport's gold by-product credits. Freeport's Q3 report showed a realized gold price of $4,273 per ounce and Grasberg throughput at 67% of capacity.